The project aims to elucidate markers of response and non-response to current treatment regimens, and to identify new therapies.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.
The Genomics Evidence Neoplasia Information Exchange aims to provide insights through the analysis of data from tens if not hundreds of thousands of patient results.
BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.
The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.
CGI will provide target identification and biomarker discovery services for three cancer drugs that BeiGene is currently developing.
The partners aim to identify a microRNA-based signature that can predict lung cancer patient response to Bristol-Myers Squibb's immunotherapy Opdivo.
The company has advanced sequencing-based copy number analyses to assess genomic instablity in CTCs, and used that to develop a method to predict response to PARP inhibitors based on the phenotype, or appearance, of genomically unstable CTCs.
The companies will discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules for cancer.
Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.
The company hopes to sequence about 60,000 whole genomes, and genotype 100,000 individuals to accelerate clinically relevant discoveries.
Researchers at the Hartwig Medical Foundation have launched a clinical trial that seeks to match tumor biomarkers with experimental and off-label drugs.
The companies said their partnership will result in a complete solution for biomarker discovery, optimization, and validation on a number of platforms.
The assay will be designed to predict how pancreatic cancer patients respond to Threshold's investigational drug evofosfamide.
Called Cedars-Sinai Precision Health, the program aims to promote novel technologies and approaches for personalized medicine at the institution.
The researchers will use genomics to address challenges facing Canada's forestry, healthcare, agricultural, and aquacultural industries.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
The clinical trial is designed to validate that biomarkers, measured in routine urine tests, effectively predict genetic mutations in drug-metabolizing enzymes.
The company has raised venture funding to support commercialization of a variety of blood-based cancer assays in Taiwan, but has yet to publish data validating its approach.
The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.
Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.
Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.
In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.